

**FOOD AND DRUG ADMINISTRATION  
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH**

**VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE**

Friday, March 10, 2000  
Holiday Inn, 8777 Georgia Avenue  
Silver Spring, Maryland

**MEETING BY TELECONFERENCE**

**AGENDA**

- |          |  |                             |
|----------|--|-----------------------------|
| Noon     | Teleconference Roll Call; Call to Order, Introductions, Administrative Matters                                 |                             |
| 12:15 PM | <u>Session 1 – Open Session</u><br><u>Completion of Formulation of Influenza Virus Vaccine for 2000 – 2001</u> |                             |
| 12:15    | Review of Current Situation  | Dr. Roland Levandowski, FDA |
| 12:25    | Additional Information on<br>Strain Surveillance and Epidemiology  | Dr. Nancy Cox, CDC          |
| 12:40    | Additional Information on Serologic<br>Results and Reference Strains   | Dr. Roland Levandowski      |
| 12:55    | Options for Strain Selection   | Dr. Roland Levandowski      |
| 1:05     | <b>Open Public Hearing</b>   |                             |
| 1:15     | Committee Discussion and Voting  |                             |
| 2:15     | <u>Session 2 – Open Session – Vaccine Safety Action Plan</u>   |                             |
| 2:15     | Briefing   | Dr. William Egan, FDA       |
| 2:45     | <b>Open Public Hearing</b>   |                             |
| 3:45     | Adjournment  |                             |

**Questions for the Committee**

1. What strain should be recommended for the influenza B component of the vaccine?
2. What strain should be recommended for the influenza A H3N2 component of the vaccine?

**Vaccines and Related Biologic Products Advisory Committee**

**March 10, 2000**

**Briefing Information**

Preliminary Information on Serologic Responses to Influenza Virus Vaccines

WHO Collaborating center for Influenza Reference and Research, Centers for  
Disease Control and Prevention